This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
by Zacks Equity Research
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency
by Urmimala Biswas
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.
5 Broker-Loved Stocks to Monitor Amid Signs of Slowing Inflation
by Maharathi Basu
Investors should keep a tab on stocks like National Vision, Cencora, ABM, Arrow Electronics and Bunge Global for high returns.
MCK Stock Gains 4% in 3 Weeks: Should You Buy, Hold or Sell?
by Indrajit Bandyopadhyay
McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Will MCK overcome its sustaining challenges with robust finances and innovation?
Masimo Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com featured highlights include The Walt Disney, Leidos, Raymond James Financial, Cencora and Delta Air Lines
by Zacks Equity Research
The Walt Disney, Leidos, Raymond James Financial, Cencora and Delta Air Lines have been highlighted in this Screen of The Week article.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bet on 5 Stocks With High ROE as Markets Surge on Cooling Inflation
by Supriyo Bose
DIS, LDOS, RJF, COR and DAL are some of the stocks with high ROE to profit on signs of decelerating inflationary pressures.
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Merit Medical Stock Gains Following Solid Preliminary Q4 Revenues
by Zacks Equity Research
MMSI's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Teladoc Partners With Amazon to Expand Chronic Care Program Reach
by Zacks Equity Research
TDOC collaborates with Amazon to enhance its reach for chronic condition management programs.
Inspire Medical Stock Falls Despite Solid Preliminary Q4 Revenues
by Zacks Equity Research
INSP's revenue growth in the fourth quarter is likely to have been boosted by increased market penetration in existing centers and expansion into new implanting centers.
Scoop Up These 4 GARP Stocks to Receive Handsome Returns
by Vasundhara Sawalka
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. OUT, COR, RJF and RMD are some stocks that hold promise.
Here's Why Cencora (COR) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora Stock May Gain Following the Strategic Acquisition of RCA
by Zacks Equity Research
COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.
Cencora (COR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cencora (COR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Cencora (COR) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Cencora (COR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is the Options Market Predicting a Spike in Cencora (COR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold Cencora Stock in Your Portfolio for Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cencora (COR) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GEHC Stock Up Following New Tie-Up to Boost Cancer Research and Care
by Zacks Equity Research
The latest collaboration aims to provide new opportunities to improve cancer diagnosis using GE HealthCare's technology and enhance clinical workflow.